Novavax (NASDAQ:NVAX): The ph3 trial has recruited ~8K individuals at a pace of ~800/day, slower than hoped for. Expects to complete enrollment in February, with analysis in late March or early April.https://seekingalpha.com/news/3650838-jnjs-covidminus-19-jab-receive-emergency-approval-next-month-official
No Alejandro, esta vez no quiero riesgos. No es falta de confianza en Nvax, es falta de confianza en la cotización.Un saludo.PD: Os llegan los emails de los temas a los que estáis suscritos ?? A mi me han dejado de llegar y no se el motivo (gmail)
Si estoy en lo cierto, están ejecutando los derechos de opciones para vender a precios actuales, antes de resultados ? :( https://ir.novavax.com/static-files/12f56b45-e164-47ea-83e5-5a6cc47dcd22TRIZZINO JOHN
MODERNA : We just announced that the first adolescent participants have been dosed in the Phase 2/3 study of mRNA-1273, our vaccine candidate against COVID-19, in adolescents ages 12 to less than 18. Read more: https://buff.ly/2Iz5li6 J&J : Johnson & Johnson is cutting the size of its pivotal U.S. Covid-19 vaccine trial — the only major study testing a single dose of a Covid vaccine — from 60,000 volunteers to 40,000 volunteers.